BIOCAD was authorized to conduct an international multicentre clinical trial (MCT) of its immunooncoprotein Prolgolimab in Slovakia and Hungary. This is the first product of the company to apply for the European market. The manufacturer also plans to launch research in Europe on the drug for the treatment of psoriasis Efleira (nontakimab).

At least 292 patients from Russia, China and EU countries will be attracted to Progolimab MCT in two European countries. It is planned to invest at least 25 million Euros in conducting MCT. Successful completion of the trials will make it possible to bring the drug to Europe and China. In Slovakia and Hungary prolgolimab is studied on the indication of "non-small cell lung cancer".

In Russia, the prolgolimab clinical trials have been completed on patients with nonresectable melanoma, with other indications still in progress. BIOCAD expects to register the prolgolimab in Russia in the first quarter of 2020.

BIOCAD is also planning to conduct MCT in Europe for Efleira (nontakimab), a drug registered in Russia in April 2019. The company spent 737 million rubles on the development of Prolgolimab and 568 million rubles on Nontakimab.

In September 2019, BIOCAD announced the establishment of a joint venture (JV) with Shanghai Pharmaceuticals Holding (SPH) of China. Under the terms of the agreement, the Russian company will grant SPH permanent and exclusive rights to develop, manufacture and commercialize six of its own biopharmaceutical products, including nethakimab and prololimab.

The JV is expected to register drugs in China in three to four years, BIOCAD CEO Dmitry Morozov said. And the company will be able to conduct clinical trials at late stages not only in China but also in Europe.

Netakimab is included in the list of Life Support Services for 2020. Regional health care institutions are already buying the drug: from May 2019 it was ordered for a total of 25 million rubles. Prolgolimab, in its turn, may become a competitor of the antitumor Opdive and Kitruda. According to Vademecum, the market for government orders of these drugs in the first half of 2019 amounted to almost 7 billion rubles.

BIOCAD is a Russian biotechnology company, whose product portfolio is based on products for the treatment of cancer, HIV infection, hepatitis and multiple sclerosis. According to SPARK-Interfax, BIOCAD's revenue in 2018 amounted to 17.8 billion rubles, net profit - 7.5 billion rubles. The company owns 70% of Vector-Biofarm, allocated in 2018 from "Pharmstandart" by Victor Kharitonin for investment activities, and 30% - the founder of BIOCAD Dmitry Morozov.